A Director at Integra Lifesciences (IART) is Buying Shares


Today, a Director at Integra Lifesciences (IART), Barbara Hill, bought shares of IART for $199.7K.

Following Barbara Hill’s last IART Buy transaction on November 01, 2017, the stock climbed by 7.7%. This recent transaction increases Barbara Hill’s holding in the company by 6.21% to a total of $3.41 million.

See today’s analyst top recommended stocks >>

Based on Integra Lifesciences’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $366 million and quarterly net profit of $13.3 million. In comparison, last year the company earned revenue of $279 million and had a net profit of $3.16 million. IART’s market cap is $4.59B and the company has a P/E ratio of 54.20. Currently, Integra Lifesciences has an average volume of 1.12M.

Based on 11 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $62.10, reflecting a 11.9% upside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy IART. Five different firms, including BTIG and Jefferies, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $2.95M worth of IART shares and purchased $199.7K worth of IART shares. The insider sentiment on Integra Lifesciences has been negative according to 76 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts